Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables - Other (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Receivables - Other over the past 3 years, most recently at $3.5 million for Q4 2025.

  • Quarterly results put Receivables - Other at $3.5 million for Q4 2025, up 265.69% from a year ago — trailing twelve months through Dec 2025 was $3.5 million (up 265.69% YoY), and the annual figure for FY2025 was $3.5 million, up 265.69%.
  • Receivables - Other for Q4 2025 was $3.5 million at Tonix Pharmaceuticals Holding, up from $1.7 million in the prior quarter.
  • Over the last five years, Receivables - Other for TNXP hit a ceiling of $4.6 million in Q4 2023 and a floor of $758000.0 in Q3 2023.
  • Median Receivables - Other over the past 3 years was $1.8 million (2025), compared with a mean of $2.1 million.
  • Biggest five-year swings in Receivables - Other: tumbled 79.24% in 2024 and later skyrocketed 265.69% in 2025.
  • Tonix Pharmaceuticals Holding's Receivables - Other stood at $4.6 million in 2023, then tumbled by 79.24% to $953000.0 in 2024, then skyrocketed by 265.69% to $3.5 million in 2025.
  • The last three reported values for Receivables - Other were $3.5 million (Q4 2025), $1.7 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.